Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma-Reference-Cited by-同舟云学术

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Published:2013-07-25 Issue:4 Volume:122 Page:499-506
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Matasar Matthew J.¹²,Czuczman Myron S.³,Rodriguez Maria Alma⁴,Fennessy Michael⁵,Shea Thomas C.⁶,Spitzer Gary⁷,Lossos Izidore S.⁸,Kharfan-Dabaja Mohamed A.⁹,Joyce Robin¹⁰,Fayad Luis⁴,Henkel Kristen¹,Liao Qiming¹¹,Edvardsen Klaus¹²,Jewell Roxanne C.¹¹,Fecteau Doug¹²,Singh Rajendra P.¹³,Lisby Steen¹⁴,Moskowitz Craig H.¹²

Affiliation:

1. Lymphoma and Adult Bone Marrow Transplant Services, Memorial Sloan-Kettering Cancer Center, New York, NY;

2. Department of Medicine, New York-Presbyterian Weill Cornell Medical College, New York, NY;

3. Lymphoma/Myeloma Service, Roswell Park Cancer Institute, Buffalo, NY;

4. Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX;

5. Oncology Medicines Development Center, GlaxoSmithKline, Middlesex, United Kingdom;

6. Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC;

7. Center of Excellence for Hematological Malignancies and Transplantation, Bon Secours St. Francis Hospital, Greenville, SC;

8. Division of Hematology Oncology, University of Miami, Miami, FL;

9. Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL;

10. Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA;

11. Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC;

12. Oncology Medicines Development Center, GlaxoSmithKline, Collegeville, PA;

13. Clinical Pharmacology Modeling & Simulation, GlaxoSmithKline, King of Prussia, PA; and

14. Medical Department, Genmab A/S, Copenhagen, Denmark

Abstract

Key Points Replacing rituximab with ofatumumab in second-line therapy for intermediate grade lymphoma does not increase toxicity; ORR/CR are encouraging. An ongoing randomized phase III trial will compare rituximab with ofatumumab, combined with chemotherapy, in relapsed or refractory DLBCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/4/499/1372889/499.pdf

Reference29 articles.

1. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.;Sehn;J Clin Oncol,2005

2. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data.;Komrokji;Clin Lymphoma Myeloma Leuk,2011

3. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.;Gisselbrecht;J Clin Oncol,2010

4. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.;Smith;Oncogene,2003

5. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.;Barth;Br J Haematol,2012

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma;Nature Medicine;2024-01-17

2. A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas;Lymphatics;2024-01-05

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis;Cancer Research and Treatment;2023-07-15

5. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma;Annals of Hematology;2023-06-12